LMP-1, E-Cadherin | |||
---|---|---|---|
PI = 0, |
PI = 0.5, |
PI = 1.0, |
|
Gender: | |||
males | 14 (15.06) | 11 (11.83) | 43 (46.24) |
females | 1 (1.08) | 6 (6.45) | 18 (19.35) |
0.14 | |||
Age (years): | |||
<20 | 0 (0.00) | 0 (0.00) | 1 (1.08) |
20 to 40 | 3 (3.23) | 5 (5.38) | 9 (9.68) |
40 to 60 | 6 (6.45) | 6 (6.45) | 31 (33.33) |
60 to 80 | 5 (5.38) | 6 (6.45) | 20 (21.51) |
>80 | 1 (1.08) | 0 (0.00) | 0 (0.00) |
0.42 | |||
Histological typea: | |||
type 1 | 0 (0.00) | 1 (1.08) | 3 (3.23) |
type 2 | 7 (7.53) | 5 (5.38) | 14 (15.05) |
type 3 | 8 (8.60) | 11 (11.83) | 44 (47.31) |
0.42 | |||
Stage: | |||
I | 0 (0.00) | 0 (0.00) | 0 (0.00) |
II | 4 (4.30) | 10 (10.75) | 19 (20.43) |
III | 5 (5.38) | 3 (3.23) | 7 (7.53) |
IV | 6 (6.45) | 4 (4.30) | 35 (37.63) |
0.04 |
For evaluation of |
For evaluation of |
---|---|
Primers [Refs.] | Sequences (5’>3’) |
LMP-1-F [ |
CAG TCA GGC AAG CCT ATG A |
LMP-1-R [ |
CTG GTT CCG GTG GAG ATG A |
GAPDH-F [ |
TGC CTC CTG CAC CAC CAA CT |
GAPDH-R [ |
CGC CTG CTT CAC CAC CTT C |
LMP-1 | E-Cadherin | |||
---|---|---|---|---|
Positive, |
Negative, |
Methylated, |
Unmethylated, |
|
Gender: | ||||
males | 51 (54.83) | 17 (18.28) | 46 (49.46) | 22 (23.66) |
females | 20 (21.51) | 5 (5.38) | 22 (23.66) | 3 (3.23) |
0.06 | 0.05 | |||
Age (years):<20 | 1 (1.08) | 0 (0.00) | 1 (1.08) | 0 (0.00) |
20 to 40 | 11 (11.83) | 6 (6.45) | 12 (12.90) | 5 (5.38) |
40 to 60 | 36 (38.71) | 7 (7.53) | 32 (34.41) | 11 (11.83) |
60 to 80 | 23 (24.73) | 8 (8.60) | 23 (24.73) | 8 (8.60) |
>80 | 0 (0.00) | 1 (1.08) | 0 (0.00) | 1 (1.08) |
0.19 | 0.52 | |||
Histological typea: | ||||
type 1 | 3 (3.23) | 1 (0.00) | 4 (4.30) | 0 (0.00) |
type 2 | 17 (18.28) | 9 (9.68) | 16 (17.20) | 10 (10.75) |
type 3 | 51 (54.83) | 12 (12.90) | 48 (51.61) | 15 (16.13) |
0.29 | 0.16 | |||
Stage: | ||||
I | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
II | 26 (27.96) | 7 (7.53) | 22 (23.66) | 11 (11.83) |
III | 8 (8.60) | 7 (7.53) | 9 (9.68) | 6 (6.45) |
IV | 37 (39.78) | 8 (8.60) | 37 (39.78) | 8 (8.60) |
0.07 | 0.14 |
Gender: | |
males | 68 (73.12) |
females | 25 (26.88) |
Age (years: | |
<20 | 1 (1.08) |
20 to 40 | 17 (18.28) |
40 to 60 | 43 (46.23) |
60 to 80 | 31 (33.33) |
>80 | 1 (1.08) |
Histological typea: | |
type 1 | 4 (4.30) |
type 2 | 26 (27.96) |
type 3 | 63 (67.74) |
Stage: | |
I | 0 (0.00) |
II | 33 (35.48) |
III | 15 (16.13) |
IV | 45 (48.39) |
Positive, |
Negative, |
||
---|---|---|---|
positive, |
61 (65.59) | 7 (7.53) | <0.0001 |
negative, |
10 (10.75) | 15 (16.13) |